Julien Ouaddour, an analyst from Bank of America Securities, maintained the Buy rating on Alcon. The associated price target remains the same with CHF89.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Julien Ouaddour has given his Buy rating due to a combination of factors influencing Alcon’s performance. Despite a slight miss in sales and EBIT in the second quarter of fiscal year 2025, the company’s core EPS exceeded expectations by 6%, primarily due to a lower tax rate. This indicates a strong underlying financial health that supports the Buy recommendation.
Additionally, although there was a revision in the full-year guidance with a reduction in expected revenue and EBIT margin, the EPS remained unchanged. This stability in earnings, coupled with anticipated benefits from upcoming product launches like Unity, suggests potential for improvement in the second half of the year. Ouaddour believes that Alcon’s management must capitalize on these opportunities to restore credibility, and the expected growth in the latter half of the year, along with a promising outlook for 2026, justifies maintaining the Buy rating.
According to TipRanks, Ouaddour is a 4-star analyst with an average return of 24.1% and an 83.33% success rate. Ouaddour covers the Healthcare sector, focusing on stocks such as Fresenius Medical Care AG & Co. KGaA, Alcon, and Amplifon S.p.A..
In another report released today, UBS also maintained a Buy rating on the stock with a CHF100.00 price target.